Brief: Tiziana Life Sciences Announces Completion Of Prerequisite Pre-Clinical Safety Study
15/12/2022 14:06
Dec 15 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES COMPLETION OF PREREQUISITE
PRE-CLINICAL SAFETY STUDY
* TIZIANA LIFE SCIENCES - STUDY SHOWED INTRANASAL FORALUMAB,
ADMINISTERED TO TRANSGENIC MICE AT DOSES UP TO 50 ΜG/RODENT, WAS
CLINICALLY WELL TOLERATED
Source text for Eikon: ID:nGNX4TtsVv
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study